Aktie A0BMJN SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Shin Nippon Biomedical Laboratories, Ltd.

Aktien

A0BMJN

JP3379950003

2395

Verzögert Japan Exchange
Andere Börsenplätze
 02:49:28 26.06.2024 		% 5 Tage % 1. Jan.
1.461 JPY +1,18 % Intraday Chart für Shin Nippon Biomedical Laboratories, Ltd. +2,24 % -13,96 %
08.05. Shin Nippon Biomedical Laboratories, Ltd. stellt konsolidierte Gewinnprognosen für die sechs Monate bis zum 30. September 2024 und das Jahr bis zum 31. März 2025 vor CI
02.02. Shin Nippon Biomedical Laboratories, Ltd. gibt konsolidierte Gewinnprognose für das Jahr bis zum 31. März 2024 ab CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Shin Nippon Biomedical Laboratories, Ltd. Announces Fiscal Year End Dividend for the Fiscal Year Ended March 31, 2024, Payable on June 25, 2024; Provides Second Quarter End and Fiscal Year End Dividend Guidance for the Fiscal Year Ended March 31, 2025
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Forecasts for the Six Months Ending September 30, 2024 and Year Ending March 31, 2025
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024
Shin Nippon's STS101 Faces Regulatory Hurdle, FDA Requests Refinement for Approval
Shin Nippon Biomedical Laboratories : 英語版 株主通信（2023/04/01~2023/09/30）を発行しました
Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending March 31, 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending March 31, 2024
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be presented at the American Headache Society's 65th Annual Scientific Meeting
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 65th Annual Scientific Meeting
Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers.
Shin Nippon Biomedical Laboratories, Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024
Shin Nippon Biomedical Laboratories, Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024
Shin Nippon Biomedical to Make $30 Million Offer for US-based Satsuma Pharmaceuticals
Sector Update: Health Care Stocks Higher Premarket Monday
Bank Earnings in Focus as US Equity Futures Tread Water
Top Premarket Gainers
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A0BMJN Aktie
  4. Nachrichten Shin Nippon Biomedical Laboratories, Ltd.
  5. Andere Sprachen